^
    Back
    Association details:
    Biomarker:HER-2 positive
    Cancer:Bladder Cancer
    Drug:Kadcyla (ado-trastuzumab emtansine) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for HER2 Positive Breast Cancer)
    New
    Title:

    Trastuzumab emtansine (Kadcyla®) is accepted for use within NHSScotland.

    Excerpt:
    Trastuzumab emtansine...as a single agent, is indicated for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors

    Excerpt:
    ...- Histologically centrally confirmed HER2-positive (immunohistochemistry [IHC]3+ in greater than or equal to [>/=] 30 percent [%] of tumor cells): locally advanced (unresectable and...
    Trial ID:
    KAMELEON
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Med
    Title:

    Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma

    Published date:
    04/29/2023
    Excerpt:
    In conclusion, KAMELEON showed that some patients with HER2-positive UBC or PC can respond to T-DM1 and provided insight into the prevalence of HER2 positivity and expression patterns in three non-breast tumor types.
    DOI:
    10.1002/cam4.5893
    Trial ID:
    KAMELEON